A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2006
11/30/2006	CA2624090A1 Peritoneum protecting agent
11/30/2006	CA2613337A1 Nk-b inhibitors for the treatment of muscular dystrophy
11/30/2006	CA2610647A1 Novel inhibitors of pyruvate kinase as therapeutic agents for cancer
11/30/2006	CA2610366A1 Selective apoptotic induction in cancer cells including activation of procaspase-3
11/30/2006	CA2610357A1 Antibody or antibody fragment coupled with an immunogenic agent
11/30/2006	CA2610067A1 Enhanced indolinone based protein kinase inhibitors
11/30/2006	CA2610025A1 Scopolamine for the treatment of depression and anxiety
11/30/2006	CA2610017A1 Compositions and methods for treating tissue
11/30/2006	CA2609980A1 Treatment of protein folding disorders
11/30/2006	CA2609875A1 Crystalline solid forms of tigecycline and methods of preparing same
11/30/2006	CA2609852A1 Cyclic amine derivative having substituted alkyl group
11/30/2006	CA2609747A1 Novel 8-sulfonylamino-3 aminosubstituted chroman or tetrahydronaphthalene derivatives modulating the 5ht6 receptor
11/30/2006	CA2609735A1 Novel 8-sulfonyl-3 aminosubstituted chroman or tetrahydronaphthalene derivatives modulating the 5ht6 receptor
11/30/2006	CA2609726A1 17.beta.-hsd1 and sts inhibitors
11/30/2006	CA2609719A1 Pediatric formulation of topiramate
11/30/2006	CA2609677A1 Bacterial cellulose-containing formulations and method of producing effective bacterial cellulose-containing formulations
11/30/2006	CA2609662A1 (r)-n-methylnaltrexone, processes for its synthesis and its pharmaceutical use
11/30/2006	CA2609659A1 Azanaphthalenes, compositions and methods for treating retinal disease
11/30/2006	CA2609627A1 Pharmaceutical formulations useful for inhibiting acid secretion
11/30/2006	CA2609612A1 Use of huperzine to treat epilepsy
11/30/2006	CA2609595A1 Preventive and/or therapeutic agents for diabetic vascular disorders and respiratory disorders
11/30/2006	CA2609549A1 Treatment of eye disorders with sirtuin modulators
11/30/2006	CA2609511A1 Polymorphic forms of (s)-1-cyanobutan-2-yl (s)-1-(3-(3-(3-methoxy-4-(oxazol-5-yl) phenyl) ureido) phenyl) ethylcarbamate
11/30/2006	CA2609508A1 Pyrrolopyridine-based inhibitors of dipeptidyl peptidase iv and methods
11/30/2006	CA2609506A1 Processes for production of 4-(biphenylyl)azetidin-2-one phosphonic acids
11/30/2006	CA2609489A1 Crystalline form of benzazepinium maleate derivative
11/30/2006	CA2609456A1 Localized delivery of cardiac inotropic agents
11/30/2006	CA2609454A1 Agent having antiobesity activity and method of inhibiting obesity
11/30/2006	CA2609446A1 Activator for peroxisome proliferator-activated receptor
11/30/2006	CA2609394A1 Pyrazole compound and therapeutic agent for diabetes comprising the same
11/30/2006	CA2609393A1 (s)-n-methylnaltrexone, process for its synthesis and its pharmaceutical use
11/30/2006	CA2609392A1 Modulators of atp-binding cassette transporters
11/30/2006	CA2609391A1 Quinazolinones
11/30/2006	CA2609389A1 Combination therapy comprising a diaryl urea compound and a pi3, akt kinase or mtor inhibitors (rapamycins) for cancer treatment
11/30/2006	CA2609387A1 Combination therapy comprising diaryl ureas for treating diseases
11/30/2006	CA2609385A1 Thienopyridines
11/30/2006	CA2609378A1 Methods and compositions for regulating biofilm development
11/30/2006	CA2609369A1 Composition for the treatment of multiple sclerosis
11/30/2006	CA2609353A1 Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
11/30/2006	CA2609330A1 Solid compositions and methods for treating middle-of-the night insomnia
11/30/2006	CA2609270A1 Hydantoin compounds
11/30/2006	CA2609235A1 Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
11/30/2006	CA2609224A1 Derivatives of 4-or 5-aminosalicylic acid
11/30/2006	CA2609215A1 Method for the treatment of noise phobia in companion animals
11/30/2006	CA2609202A1 Apoptosis promoters
11/30/2006	CA2609192A1 Oral dosage forms comprising progesterone and methods of making and using the same
11/30/2006	CA2609188A1 Apo-2 ligand/trail formulations
11/30/2006	CA2609186A1 Methods of synthesizing substituted 3-cyanoquinolines and intermediates thereof
11/30/2006	CA2609180A1 Modulation of lmw-ptpase expression
11/30/2006	CA2609158A1 Use of glycerol for improving cardiac function
11/30/2006	CA2609126A1 Pyrrolopyridines useful as inhibitors of protein kinase
11/30/2006	CA2609004A1 Tetrahydropyridothiophenes for use in the treatment of cancer
11/30/2006	CA2609003A1 Tetrahydropyridothiophenes for use in the treatment of cancer
11/30/2006	CA2608850A1 Methods for diagnosing epigenetic, transgenerational effects of environmental toxicants on mammalian germ-lines and treating associated diseases
11/30/2006	CA2608687A1 New antibiotic derivatives
11/30/2006	CA2608685A1 Substituted piperidines as renin inhibitors
11/30/2006	CA2608678A1 Organic compounds
11/30/2006	CA2608672A1 Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
11/30/2006	CA2608651A1 Compositions and methods for the prevention and treatment of conditions associated with inflammation
11/30/2006	CA2608573A1 Gel compositions for control of ecto-parasites
11/30/2006	CA2608375A1 Organic compounds for the treatment of inflammatory or alleric conditions
11/30/2006	CA2608220A1 Methods and compositions using 4[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperridin-3yl) isoindole-1,3-dione for the treatment of prevention of cutaneous lupus
11/30/2006	CA2608153A1 Thiazole derivatives for use as p13k modulators
11/30/2006	CA2608143A1 Thiazole derivatives and use thereof
11/30/2006	CA2608134A1 Phospholipids for use in the treatment of an allergic inflammatory condition
11/30/2006	CA2608072A1 Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
11/30/2006	CA2608036A1 Medicated product for local use based on natural materials
11/30/2006	CA2607857A1 Inhibitors of cytosolic phospholipase a2
11/30/2006	CA2607441A1 Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
11/30/2006	CA2607385A1 Thiazole derivatives and their use for the treatment and/or prophylaxis of disorders and diseases
11/30/2006	CA2607280A1 Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists
11/30/2006	CA2606499A1 Thyromimetics for the treatment of fatty liver diseases
11/30/2006	CA2606498A1 Novel phosphinic acid-containing thyromimetics
11/30/2006	CA2605764A1 Amorphous cinacalcet hydrochloride and preparation thereof
11/30/2006	CA2605736A1 Purification of cinacalcet
11/30/2006	CA2604165A1 Novel substituted tetracyclic tetrahydrofuran, pyrrolidine and tetrahydrothiophene derivatives and their use as a medicament
11/30/2006	CA2602965A1 Tricyclic spiro derivatives as crth2 modulators
11/30/2006	CA2602854A1 Compounds for the treatment of metabolic disorders
11/29/2006	EP1726952A1 Method of in vivo screening of therapeutic agent for memory/learning dysfunction by schizophrenia
11/29/2006	EP1726656A2 Metalloproteinase-disintegrin family members: SVPH DNAs and polypeptides
11/29/2006	EP1726652A2 Delta 6-desaturases from primulaceae, expressing plants and PUFA-containing oils
11/29/2006	EP1726651A1 Method of treating muscular disorders
11/29/2006	EP1726647A1 Gene promoting vascular endothelial cell growth
11/29/2006	EP1726592A1 Dioxino derivatives and their use as dopanine agonists
11/29/2006	EP1726590A1 Cycloalkanopyridine derivative
11/29/2006	EP1726589A2 5,5'-bis-(4-amidinophenyl)-2,2'-bifuran derivatives and related compounds as antiprotozoal agent and prodrugs thereof
11/29/2006	EP1726587A1 Benzothiazin-3-one compound and intermediate therefor
11/29/2006	EP1726586A1 Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient
11/29/2006	EP1726585A1 Diaryl-substituted five-membered heterocycle derivative
11/29/2006	EP1726584A1 2-aminoquinazoline derivative
11/29/2006	EP1726582A2 Compounds and methods for the inhibition of the expression of vcam-1
11/29/2006	EP1726580A1 Aminophenylpropanoic acid derivative
11/29/2006	EP1726313A1 Drug for preventing and treating arteriosclerosis
11/29/2006	EP1726308A2 Composition for contraception comprising an estrogen and a gestagen
11/29/2006	EP1726307A2 Methods for treating psychosis associated with glucocorticoid related dysfunction
11/29/2006	EP1726306A1 Fasudil-containing preparation and method of improving stability thereof
11/29/2006	EP1726305A1 Zinc salt of omeprazole and its enantiomers
11/29/2006	EP1726304A1 Solifenacin-containing composition
11/29/2006	EP1726303A1 Therapeutic agent for renal anemia
11/29/2006	EP1726302A2 Transdermal therapeutic system suitable for heat application to promote the permeation of active substances, as well as use thereof

1 ... 3987 3988 3989 3990 3991 3992 3993 3994 3995 3996 3997 3998 3999 4000 4001 4002 4003 4004 4005 4006 4007 ... 7860